Dermatology and Therapy Review Explores Dermal Aging as a Visible Indicator of Systemic Health Span in Menopause

A newly published narrative review suggests that perimenopausal and menopausal skin changes driven by estrogen deficiency can serve as visible indicators of systemic tissue decline, providing clinicians with a unique opportunity to address overall longevity and healthspan.

A narrative review co-authored by researchers from Brigham Young University, Amway Corporation, and Dermatology Consulting Services was published in Dermatology and Therapy, detailing the impact of perimenopause and menopause on skin health.

The review establishes that estrogen deficiency drives noticeable chronological and photo-aging of the skin, which the authors suggest acts as a reflective mirror for the potential decline of internal, unseen tissue and organ systems.

The authors evaluated potential therapeutic strategies, including hormonal treatments, selective estrogen receptor modulators (SERMs), and polyphenolic or isoflavonoid treatments, alongside lifestyle factors.

By framing the skin as an observable organ that mirrors internal physiological states, the review proposes a clinical shift where dermatologists and nutritional professionals can initiate broader conversations regarding female healthspan and systemic aging.

This paradigm moves dermal treatments beyond cosmetic intervention, linking outer appearance directly to internal health and metabolic aging.

The clinical positioning of dermal aging as a surrogate marker for systemic decline could drive demand for multi-functional longevity therapeutics that address both hormonal pathways and tissue-specific aging.

It highlights the strategic importance of reproductive longevity as an emerging sub-sector within the global healthspan market, aligning with growing consumer and clinical interest in menopause-related health.

Further clinical studies validating the correlation between specific dermal aging patterns and internal organ function or biomarker shifts in menopausal women.

The development of novel tissue-selective estrogen receptor modulators (SERMs) or polyphenol-based nutraceuticals aimed at simultaneously preserving skin and systemic tissue health.